



## **MORVUS TECHNOLOGY EMBARKS ON DIAGNOSTICS PROJECT WITH CARDIFF UNIVERSITY**

**July 12<sup>th</sup> 2010, Carmarthen.** Morvus Technology Limited (“Morvus”), the UK-based pharmaceutical company focused on the oncology market, today announces that it has embarked on a collaborative venture with Cardiff University School of Medicine to research and develop rapid diagnostic tests for genitourinary cancers.

The £100,000 project, which will be carried out in partnership with Professor Ian Weeks of the Department of Infection, Immunity and Biochemistry and Professor Howard Kynaston of the Department of Surgery and will also involve collaboration with Cardiff and Vale University Health Board, will initially focus on bladder cancer and has been awarded a £74,500 grant from the National Institute for Health Research’s i4i programme. Professor Weeks has been involved in diagnostic technology research for over 25 years and his work has formed the basis of numerous commercially successful diagnostic tests. Professor Kynaston is one of the UK’s leading experts on urological malignancy.

In the UK more than 10,000 new cases of bladder cancer are diagnosed every year and, although treatment is generally successful, recurrence of the tumours requires regular hospital examination to manage the condition. “There is a clear need for a rapid, non-invasive diagnostic test for recurrent bladder cancer” said Professor Weeks. “Such a test will be less burdensome to patients and will considerably reduce costs to the healthcare system”.

Phil Burke, the CEO of Morvus, said: “This work will address an area of unmet medical need and is potentially capable of making a significant difference to the lives of many cancer patients”.

### **About Morvus Technology Ltd.**

Morvus Technology is a privately-owned company engaged in the discovery, development and commercialisation of novel drugs for the oncology market. The Company was established in 2004 and has offices and laboratories near Carmarthen, South West Wales. Morvus has a broad portfolio of technology which is focused on disease areas for which there is a clear, unmet medical need.

**CONTACT:**

Dr Phil Burke

Chief Executive

[pburke@morvus.com](mailto:pburke@morvus.com)

Tel: 01558 667 184